Search Clinical Trials
Active, Not Recruiting
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (External Link)
The patient or their donor will give us blood to make CD19-CD28 chimeric receptor T cells and CD19 chimeric-EBV specific T cells in the laboratory. These cells are grown and …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (External Link)
The donor gave us blood to make CD19 chimeric receptor trivirus specific T cells in the laboratory. These cells were grown and frozen for the subject. To make these special …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (External Link)
Patients will give us blood to make CD19 CD28 chimeric receptor-T cells in the laboratory. These cells will be grown and frozen for the patient. To make the T cells …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene (External Link)
Because the patient will receive cells with a new gene in them, they will be followed for a total of 15 years to see if there are any long-term side …
Baylor Role:
Lead Sponsor
Completed
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR (External Link)
To participate in this study, patients will need to have given informed consent to have a bone marrow transplant. Before receiving the tetanus vaccine, we would like to test the …
Baylor Role:
Collaborator
Completed
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD (External Link)
Participation in this protocol will last about 1 year. To participate in this study, the patient will need to have undergone a stem cell transplant. Before the treatment starts, investigators …
Baylor Role:
Lead Sponsor
Terminated
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) (External Link)
Allogeneic stem cell transplantation with high-dose chemotherapy affords a better chance of cure of malignant and non-malignant hematological diseases compared to autologous transplantation, because of the lack of stem cell …
Baylor Role:
Lead Sponsor
Completed
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells (External Link)
Previously, some of the cancer cells taken from the patients body were separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was put …
Baylor Role:
Lead Sponsor
Withdrawn
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells (External Link)
This is a phase I trial to assess the safety of depleting regulatory T (Treg) cells using 1-3 doses of an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, …
Baylor Role:
Lead Sponsor
Completed
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation (External Link)
Patients are given high doses of chemotherapy before receiving a stem cell transplant to keep their immune system from rejecting the donor stem cells and to kill any diseased cells …
Baylor Role:
Lead Sponsor